UCB   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Brussels Belgium (1928)

Organization Overview

First Clinical Trial
2016
NCT05028127
First Marketed Drug
1955
amphetamine (Adderall)
First NDA Approval
1984
chlorpheniramine (ChlorTrimeton)
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

001 844 599 22733 (UCB) | 001 844 599 2273 (UCB) | +1 844 599 2273 (UCB) | +1-844-599-2273 (UCB) | 1-844-599-2273(UCB) | +1 877 822 9493 (UCB) | 1 877 822 9493 (UCB) | 1-877-822-9493 (UCB) | UCB (+1 844 599 2273) | UCB (+1 877 822 9493) | UCB (+1 887 822 9493) | UCB Biopharma S.P.R.L. | UCB Biopharma SRL | UCB Celltech | UCB / Global Medical Affairs | UCB INC | UCB Japan Co. Ltd. | UCB Nordic A/S | UCB Pharma | UCB Pharma GmbH | UCB Pharma SA | UCB S.A. - Pharma Sector | UCB Trading (Shanghai) Co. Ltd. | UCB Young Investigator Research Program | WHITBY

Active Ingredients

Marketed Drugs (25)

Key: UCB (20) Acquired (5)

acetaminophen (tylenol) (1982)

amphetamine (Adderall) (1955)

baclofen (lioresal) (2003)

benzodiazepine (2005)

brivaracetam (briviact) (2016 NDA)

carbidopa (sinemet) (2004)

certolizumab pegol (cimzia) (2008 NDA)

chlorpheniramine (ChlorTrimeton) (1984 NDA)

dexamethasone (1962)

dextroamphetamine (Dexedrine) (1955)

famotidine (pepcid) (2004)

hydrochlorothiazide (esidrix) (1997)

hydrocodone (hycodan) (1982)

lacosamide (vimpat) (2008 NDA)

levetiracetam (keppra) (1999 NDA)

levocetirizine (xyzal) (2007 NDA)

levodopa (larodopa) (2004)

midazolam (versed) (2019)

moexipril (univasc) (1995)

phentermine (wyamine) (1959)

phenylpropanolamine (Propadrine) (1984)

pseudoephedrine (Benylin) (1987)

rotigotine (neupro) (2007)

theophylline (synophylate) (1985)

urea (1962)

Drugs in Phase 4 Trials (4)

Key: UCB (0) Acquired (4)

amitriptyline (elavil) (1 trial)

fenfluramine (Pondimin) (14 trials)

mesalamine (rowasa) (6 trials)

sumatriptan (zecuity) (2 trials)

Drugs in Phase 3 Trials (20)

Key: UCB (12) Acquired (8)

adalimumab (humira) (4 trials)

benzodiazepine (8 trials)

bimekizumab (Bimzelx) (28 trials)

brivaracetam (briviact) (12 trials)

certolizumab pegol (cimzia) (8 trials)

dapirolizumab pegol (2 trials)

ferrous glycine sulphate complex (1 trial)

hydrocodone (hycodan) (8 trials)

lacosamide (vimpat) (4 trials)

levetiracetam (keppra) (4 trials)

mesalazine (4 trials)

omega-3-carboxylic acids (epanova) (2 trials)

padsevonil (12 trials)

romosozumab (Evenity) (1 trial)

rotigotine (neupro) (4 trials)

rozanolixizumab (13 trials)

secukinumab (cosentyx) (1 trial)

ustekinumab (stelara) (1 trial)

zidovudine (retrovir) (2 trials)

zilucoplan (6 trials)

Drugs in Phase 2 Trials (12)

Key: UCB (5) Acquired (7)

acetaminophen (tylenol) (1 trial)

beclomethasone (vanceril) (1 trial)

cefuroxime (zinacef) (1 trial)

guaifenesin (1 trial)

pseudoephedrine (Benylin) (1 trial)

ra101495 (4 trials)

selodenoson (1 trial)

ucb0107 (5 trials)

ucb0599 (3 trials)

ucb6114 (1 trial)

ucb7858 (2 trials)

ucb9741 (1 trial)

Drugs in Phase 1 Trials (12)

Key: UCB (9) Acquired (3)

erythromycin (ilosone) (1 trial)

ethanol (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

lamotrigine (lamictal) (1 trial)

levonorgestrel (1 trial)

metronidazole (flagyl) (1 trial)

moxifloxacin (avelox) (1 trial)

oxcarbazepine (trileptal) (1 trial)

risperidone (risperdal) (2 trials)

ucb0022 (1 trial)

ucb7853 (1 trial)

ucb8600 (1 trial)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 160
  • # of Trial APIs: 48